Trial
NCT02725372
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Bellerophon Pulse Technologies
Collaborators
Worldwide Clinical Trials
Condition
Pulmonary Arterial Hypertension
Intervention
Inhaled Nitric Oxide 75 mcg/kg IBW/hr
Why stopped
Trial stopped for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-21